Molecular Partners

Molecular Partners is developing a novel class of therapeutic proteins, termed DARPins. DARPins equal the target binding properties of antibodies but feature superior stability and are easier to express, thus allowing novel therapeutic approaches. To date, DARPins have been generated against a high number of targets, including cell surface receptors, cytokines, proteases, kinases and viral coat proteins.

The company was incorporated in 2004 as a spin-off company of the group of Professor Andreas Plückthun at the University of Zürich. Molecular Partners owns the exclusive commercial rights in DARPins and has a complete freedom to operate in the field.

Recent News

May 30, 2017
Molecular Partners provides additional details on clinical studies of proprietary lead oncology asset MP0250

May 12, 2017
Patrick Amstutz Appointed as Chief Executive Officer

April 6, 2017
Molecular Partners discloses change in shareholder base

October 9, 2016
Molecular Partners Presents Data of MP0250 in an All-Comer Phase 1-Study in Solid Tumor Patients and Updates on Phase 2 Studies

July 21, 2015
Allergan strengthens DARPin development and discovery alliance with Molecular Partners

July 7, 2015
First patient enrolled in phase III study of abicipar - Molecular Partners receives USD 15 million milestone payment

March 17, 2015
Molecular Partners reports its results for the Financial Year 2014 ‐  A transformative year for the company

December 5, 2014
Total offer size of IPO reaches CHF 106.2 million after partial exercise of IPO over-allotment option

November 6, 2014
Molecular Partners has successfully priced its IPO post re-launch and lists its shares on SIX Swiss Exchange

October 8, 2014
Molecular Partners sets the price range for its IPO at CHF 28 to CHF 35 per share – First trading day expected for 22 October 2014

September 23, 2014
Molecular Partners launches IPO on SIX Swiss Exchange

September 22, 2014
FierceBiotech names Molecular Partners as one of its “Fierce 15” Biotech Companies of 2014

September 19, 2014
Molecular Partners appoints Steven H. Holtzman as independent non-executive member to its board of directors

July 1, 2014
Stage 3 Phase 2 study of DARPin abicipar pegol (previously MP0112) supports progressing to phase III development program

December 4, 2013
Roche and Molecular Partners enter into alliance to develop new cancer treatments

January 17, 2013
Molecular Partners Announces Publication of Results from a Phase I/II Clinical Trial of its

November 12, 2012
Molecular Partners enters into a strategic collaboration agreement with Boehringer Ingelheim to support its proprietary pipeline with clinical supply of DARPin® molecules

August 21, 2012
Allergan and Molecular Partners Enter into Exclusive Alliance

May 31, 2012
Molecular Partners AG strengthens management team with the appointment of Lisa Rojkjaer, MD as Chief Medical Officer

December 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

May 4, 2011
Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases

April 28, 2011
Molecular Partners reports positive results from its first clinical studies

February 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

September 1, 2010
Molecular Partners selected as Technology Pioneer 2011 by the World Economic Forum

December 15, 2009
Molecular Partners Secures CHF 46 Million in a Series B Financing

January 15, 2008
Molecular Partners AG collaborates with Centocor Research & Development, Inc.

August 14, 2007
Molecular Partners Raises 18.5 Mio CHF in Series A Financing


Company Info
Country: Switzerland
Industry:    Biotech
Sector: biotechnology
Status: Unrealized
Vehicle: Endeavour II LP

Key persons
 Dr. Christian Zahnd, CEO; Andreas Emmenegger, CFO; Dr. Michael Stumpp, CSO; Dr. Patrick Amstutz, CBO

Company website

Endeavour Vision Team
Sven Lingjaerde
Daniel Bertholet
© Endeavour Vision SA 2006-2017 Terms & Conditions